MX2018007074A - Moduladores de canales de kv3 para tratar dolor. - Google Patents

Moduladores de canales de kv3 para tratar dolor.

Info

Publication number
MX2018007074A
MX2018007074A MX2018007074A MX2018007074A MX2018007074A MX 2018007074 A MX2018007074 A MX 2018007074A MX 2018007074 A MX2018007074 A MX 2018007074A MX 2018007074 A MX2018007074 A MX 2018007074A MX 2018007074 A MX2018007074 A MX 2018007074A
Authority
MX
Mexico
Prior art keywords
modulators
channels
treat pain
pain
prophylaxis
Prior art date
Application number
MX2018007074A
Other languages
English (en)
Inventor
Giuseppe Alvaro
Charles Large
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of MX2018007074A publication Critical patent/MX2018007074A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/30—Compounds having groups
    • C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invención proporciona un modulador de canales Kv3.1 y/o Kv3.2 y/o Kv3.3 para su usarse en la profilaxis o el tratamiento del dolor; moduladores para usarse en la profilaxis o el tratamiento del dolor incluyen compuestos de fórmula (I) o una sal y/o solvato farmacéuticamente aceptable de los mismos y/o sus derivados. (ver Fórmula).
MX2018007074A 2015-12-10 2016-12-09 Moduladores de canales de kv3 para tratar dolor. MX2018007074A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1521751.6A GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses
PCT/GB2016/053879 WO2017098254A1 (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain

Publications (1)

Publication Number Publication Date
MX2018007074A true MX2018007074A (es) 2018-12-12

Family

ID=55274489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007074A MX2018007074A (es) 2015-12-10 2016-12-09 Moduladores de canales de kv3 para tratar dolor.

Country Status (16)

Country Link
US (2) US11147813B2 (es)
EP (1) EP3386506B1 (es)
JP (2) JP7149847B2 (es)
KR (1) KR20180097549A (es)
AU (1) AU2016367239B2 (es)
BR (1) BR112018011700B1 (es)
CA (1) CA3005302A1 (es)
DK (1) DK3386506T3 (es)
EA (1) EA038059B1 (es)
FI (1) FI3386506T3 (es)
GB (1) GB201521751D0 (es)
IL (1) IL259717B (es)
MX (1) MX2018007074A (es)
PT (1) PT3386506T (es)
SG (1) SG11201804123VA (es)
WO (1) WO2017098254A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
WO2018109484A1 (en) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
TWI827706B (zh) * 2018-10-16 2024-01-01 英商奧堤凡尼治療股份有限公司 新穎化合物
AR116898A1 (es) * 2018-10-30 2021-06-23 H Lundbeck As DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3
AU2020427632A1 (en) 2020-02-06 2022-08-18 Autifony Therapeutics Limited Kv3 modulators
KR20240046748A (ko) 2021-08-10 2024-04-09 오티포니 세라피틱스 리미티드 칼륨 채널 조절제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723626A1 (en) 2008-06-06 2009-12-10 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
CA2781685C (en) 2009-12-11 2018-09-04 Autifony Therapeutics Limited Imidazolidinedione derivatives
US9346790B2 (en) * 2010-12-06 2016-05-24 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
WO2012168710A1 (en) 2011-06-07 2012-12-13 Autifony Therapeutics Limited Hydantoin derivates as kv3 inhibitors
ES2576628T3 (es) * 2011-12-06 2016-07-08 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
JP6240667B2 (ja) 2012-05-22 2017-11-29 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのトリアゾール
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
IL259717A (en) 2018-07-31
BR112018011700B1 (pt) 2023-12-26
JP2019506367A (ja) 2019-03-07
KR20180097549A (ko) 2018-08-31
JP2022141699A (ja) 2022-09-29
IL259717B (en) 2021-05-31
BR112018011700A2 (pt) 2018-11-27
EP3386506B1 (en) 2024-01-24
FI3386506T3 (fi) 2024-04-23
JP7149847B2 (ja) 2022-10-07
SG11201804123VA (en) 2018-06-28
CN108472288A (zh) 2018-08-31
CA3005302A1 (en) 2017-06-15
EA201891377A1 (ru) 2019-01-31
US20190000848A1 (en) 2019-01-03
AU2016367239A1 (en) 2018-06-07
DK3386506T3 (da) 2024-05-06
GB201521751D0 (en) 2016-01-27
WO2017098254A1 (en) 2017-06-15
EA038059B1 (ru) 2021-06-30
AU2016367239B2 (en) 2020-07-09
US11147813B2 (en) 2021-10-19
US11944623B2 (en) 2024-04-02
PT3386506T (pt) 2024-03-28
EP3386506A1 (en) 2018-10-17
US20220071998A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2018007074A (es) Moduladores de canales de kv3 para tratar dolor.
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
PH12019502646A1 (en) Pyrazole magl inhibitors
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
MX2017015741A (es) Moduladores de ror gamma (ror?).
PH12016502352A1 (en) Pharmaceutical composition
MX2017015739A (es) Moduladores de ror gamma (ror?).
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
MX2022006862A (es) Inhibidores duales de magl y faah.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
IN2014DE00822A (es)